PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study

oleh: Ke Su, Lu Guo, Wenqiong Ma, Jing Wang, Yunchuan Xie, Mingyue Rao, Jianwen Zhang, Xueting Li, Lianbin Wen, Bo Li, Bo Li, Bo Li, Xiaoli Yang, Xiaoli Yang, Xiaoli Yang, Yanqiong Song, Weihong Huang, Hao Chi, Tao Gu, Ke Xu, Yanlin Liu, Jiali Chen, Zhenying Wu, Yi Jiang, Han Li, Hao Zeng, Pan Wang, Xunjie Feng, Siyu Chen, Binbin Yang, Hongping Jin, Kun He, Yunwei Han, Yunwei Han, Yunwei Han

Format: Article
Diterbitkan: Frontiers Media S.A. 2022-09-01

Deskripsi

BackgroundWhether intensity-modulated radiotherapy (IMRT) can enhance the efficacy of the programmed death (PD)-1 inhibitors combined with anti-angiogenic therapy for hepatocellular carcinoma (HCC) is unclear. Therefore, we conducted this multicenter retrospective study to investigate the efficacy of the combination of PD-1 inhibitors with anti-angiogenic therapy and IMRT.MethodsFrom April 2019 to March 2022, a total of 197 patients with HCC [combination of PD-1 inhibitors with anti-angiogenic therapy and IMRT (triple therapy group), 54; PD-1 inhibitors plus anti-angiogenic therapy (control group), 143] were included in our study. Propensity score matching (PSM) was applied to identify two groups with similar baselines. The objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) of the two groups were compared before and after matching.ResultsPrior to PSM, the triple therapy group had higher ORR (42.6% vs 24.5%, P = 0.013) and more superior median OS (mOS) (20.1 vs 13.3 months, P = 0.009) and median PFS (mPFS) (8.7 vs 5.4 months, P = 0.001) than the control group. Following PSM, the triple therapy group still exhibited better mPFS (8.7 vs 5.4 months, P = 0.013) and mOS (18.5 vs 12.6 months, P = 0.043) than the control group. However, the ORR of the two groups was similar (40% vs 25%, P = 0.152). No significant difference was observed in the treatment-related adverse events between the two groups (P < 0.05 for all). ConclusionsThe combination of PD-1 inhibitors with anti-angiogenic therapy and IMRT for HCC is a promising regimen.